Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway

Cancer Cell International

Volumn 15, Issue 1, 2015, Pages

  Xu, Huae ^a   Li, Xiaolin ^a   Ding, Wenqiu ^a   Zeng, Xiaoning ^a   Kong, Hui ^a   Wang, Hong ^a   Xie, Weiping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Deguelin; Lung cancer; ROS

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; DEGUELIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR MEMBRANE; LUNG CANCER; LUNG CANCER CELL LINE; MITOSIS INHIBITION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

EID: 84928739448     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-015-0166-4     Document Type: Article

References (47)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29
2. Livshits Z, Rao RB, Smith SW. An approach to chemotherapy-associated toxicity. Emerg Med Clin North Am. 2014;32:167-203
3. Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, et al. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One. 2013;8:e65113
4. Kang HW, Kim JM, Cha MY, Jung HC, Song IS, Kim JS. Deguelin, an Akt inhibitor, down-regulates NF-kappaB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Dig Dis Sci. 2012;57:2873-82
5. Ji BC, Yu CC, Yang ST, Hsia TC, Yang JS, Lai KC, et al. Induction of DNA damage by deguelin is mediated through reducing DNA repair genes in human non-small cell lung cancer NCI-H460 cells. Oncol Rep. 2012;27:959-64
6. Lee H, Lee JH, Jung KH, Hong SS. Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer. Oncol Rep. 2010;24:957-63
7. Murillo G, Salti GI, Kosmeder 2nd JW, Pezzuto JM, Mehta RG. Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur J Cancer. 2002;38:2446-54
8. Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriarty RM, et al. Downregulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol. 2007;71:101-11
9. Chu ZH, Liang XH, Zhou XL, Huang RF, Zhan Q, Jiang JW. [Effects of deguelin on proliferation and apoptosis of MCF-7 breast cancer cells by phosphatidylinositol 3-kinase/Akt signaling pathway]. Zhong Xi Yi Jie He Xue Bao. 2011;9:533-8
10. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, et al. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res. 2007;67:11630-9
11. Zhou L, Luan H, Liu Q, Jiang T, Liang H, Dong X, et al. Activation of PI3K/Akt and ERK signaling pathways antagonized sinomenine-induced lung cancer cell apoptosis. Mol Med Rep. 2012;5:1256-60
12. Puglisi M, Thavasu P, Stewart A, de Bono JS, O'Brien ME, Popat S, et al. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines. Lung Cancer. 2014;85:141-6
13. Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, et al. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis. 2014;5:e1104
14. Zhang C, Cao S, Toole BP, Xu Y: Cancer may be a pathway to cell survival under persistent hypoxia and elevated ROS: a model for solid-cancer initiation and early development. Int J Cancer 2014. doi: 10.1002/ijc.28975
15. El Sayed SM, Mahmoud AA, El Sawy SA, Abdelaal EA, Fouad AM, Yousif RS, et al. Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). Med Hypotheses. 2013;81:866-70
16. Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7:97-110
17. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002;3:420-5
18. Li X, Lu X, Xu H, Zhu Z, Yin H, Qian X, et al. Paclitaxel/tetrandrine coloaded nanoparticles effectively promote the apoptosis of gastric cancer cells based on "oxidation therapy". Mol Pharm. 2012;9:222-9
19. Li X, Xu H, Dai X, Zhu Z, Liu B, Lu X. Enhanced in vitro and in vivo therapeutic efficacy of codrug-loaded nanoparticles against liver cancer. Int J Nanomedicine. 2012;7:5183-90
20. Chetram MA, Bethea DA, Odero-Marah VA, Don-Salu-Hewage AS, Jones KJ, Hinton CV. ROS-mediated activation of AKT induces apoptosis via pVHL in prostate cancer cells. Mol Cell Biochem. 2013;376:63-71
21. Hussain AR, Uddin S, Bu R, Khan OS, Ahmed SO, Ahmed M, et al. Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One. 2011;6:e24703
22. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R, et al. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3 (-/-) mice. EMBO J. 2010;29:4118-31
23. Esmaeili MA, Farimani MM, Kiaei M. Anticancer effect of calycopterin via PI3K/Akt and MAPK signaling pathways, ROS-mediated pathway and mitochondrial dysfunction in hepatoblastoma cancer (HepG2) cells. Mol Cell Biochem. 2014;397:17-31
24. Palanivel K, Kanimozhi V, Kadalmani B, Akbarsha MA. Verrucarin a induces apoptosis through ROS-mediated EGFR/MAPK/Akt signaling pathways in MDA-MB-231 breast cancer cells. J Cell Biochem. 2014;115:2022-32
25. Cao J, Xu D, Wang D, Wu R, Zhang L, Zhu H, et al. ROS-driven Akt dephosphorylation at Ser-473 is involved in 4-HPR-mediated apoptosis in NB4 cells. Free Radic Biol Med. 2009;47:536-47
26. Dolado I, Nebreda AR. AKT and oxidative stress team up to kill cancer cells. Cancer Cell. 2008;14:427-9
27. Dall'Acqua S, Linardi MA, Bortolozzi R, Clauser M, Marzocchini S, Maggi F, et al. Natural daucane esters induces apoptosis in leukaemic cells through ROS production. Phytochemistry. 2014;108:147-56
28. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res. 2005;65:8455-60
29. Yang JC, Lu MC, Lee CL, Chen GY, Lin YY, Chang FR, et al. Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K. Free Radic Biol Med. 2011;51:641-57
30. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011;475:231-4
31. Gibson KR, Neilson IL, Barrett F, Winterburn TJ, Sharma S, MacRury SM, et al. Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity. J Cardiovasc Pharmacol. 2009;54:319-26
32. Zhu C, Hu W, Wu H, Hu X. No evident dose-response relationship between cellular ROS level and its cytotoxicity-a paradoxical issue in ROS-based cancer therapy. Sci Rep. 2014;4:5029
33. Zhang H, Li X, Ding J, Xu H, Dai X, Hou Z, et al. Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int J Pharm. 2013;441:261-8
34. Shao J, Zheng D, Jiang Z, Xu H, Hu Y, Li X, et al. Curcumin delivery by methoxy polyethylene glycol-poly (caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim Biophys Sin (Shanghai). 2011;43:267-74
35. Li X, Zhen D, Lu X, Xu H, Shao Y, Xue Q, et al. Enhanced cytotoxicity and activation of ROS-dependent c-Jun NH2-terminal kinase and caspase-3 by low doses of tetrandrine-loaded nanoparticles in Lovo cells-a possible Trojan strategy against cancer. Eur J Pharm Biopharm. 2010;75:334-40
36. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, et al. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst. 2007;99:949-61
37. Yang YL, Ji C, Bi ZG, Lu CC, Wang R, Gu B, et al. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. PLoS One. 2013;8:e54736
38. Abraham J. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? Expert Rev Anticancer Ther. 2014;151:1-18
39. Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. Lung Cancer Manag. 2014;3:67-75
40. Xing CG, Zhu BS, Fan XQ, Liu HH, Hou X, Zhao K, et al. Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. World J Gastroenterol. 2009;15:5044-52
41. Yun J, Lv YG, Yao Q, Wang L, Li YP, Yi J. Wortmannin inhibits proliferation and induces apoptosis of MCF-7 breast cancer cells. Eur J Gynaecol Oncol. 2012;33:367-9
42. Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A, et al. Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol. 2005;129:677-86
43. McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, et al. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Adv Enzyme Regul. 2008;48:113-35
44. Chen X, Wang H, Ou-Yang XN, Xie FW, Wu JJ. Research on drug resistance mechanism of trastuzumab caused by activation of the PI3K/Akt signaling pathway. Contemp Oncol (Pozn). 2013;17:363-9
45. Jiang S, Zhu W, Wu J, Li C, Zhang X, Li Y, et al. alpha-lipoic acid protected cardiomyoblasts from the injury induced by sodium nitroprusside through ROS-mediated Akt/Gsk-3beta activation. Toxicol In Vitro. 2014;28:1461-73
46. Yuan L, Wei S, Wang J, Liu X. Isoorientin induces apoptosis and autophagy simultaneously by reactive oxygen species (ROS)-related p53, PI3K/Akt, JNK, and p38 signaling pathways in HepG2 cancer cells. J Agric Food Chem. 2014;62:5390-400
47. Xu H, Hou Z, Zhang H, Kong H, Li X, Wang H, et al. An efficient Trojan delivery of tetrandrine by poly (N-vinylpyrrolidone)-block-poly (epsilon-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion. Int J Nanomedicine. 2014;9:231-42